A Phase II Trial Investigating the Benefit of Immunotherapy With Durvalumab After Autologous Transplant in High-risk Diffuse-large B-cell Lymphomas (the IDA-D Trial)

Trial Profile

A Phase II Trial Investigating the Benefit of Immunotherapy With Durvalumab After Autologous Transplant in High-risk Diffuse-large B-cell Lymphomas (the IDA-D Trial)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms IDA-D
  • Most Recent Events

    • 05 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 09 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top